Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label mass balance and pharmacokinetics study of radiolabeled RO7034067 in healthy men
NL-OMON57832Completed
- Sponsor
- Roche
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of risdiplam in spinal muscular atrophy (SMA), sponsored by Roche. Primary endpoints: Mass balance and elimination of [14C]-labeled RO7034067 and Pharmacokinetics of total radioactivity, RO7034067 and metabolites. Started Nov 2016; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON57832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57832.